MRK

Jeito Capital announces the acquisition by Merck & Co (NYSE: MRK) of its portfolio company EyeBio for a potential value of $3 billion

Retrieved on: 
onsdag, maj 29, 2024
MSD, Patient, BIIB, Doctor of Philosophy, Retina, Biogen, Clinical trial, Hart–Scott–Rodino Antitrust Improvements Act, MD, DME, Research, CSO, Acquisition, WNT, Merck & Co., Diabetic retinopathy, MRK, Paratriathlon, Entrepreneurship, Pharmaceutical industry

The transaction is expected to close in the third quarter of 2024.

Key Points: 
  • The transaction is expected to close in the third quarter of 2024.
  • EyeBio is developing a pipeline of clinical and preclinical stage candidates for the prevention and treatment of vision loss associated with retinal vascular leakage, a known risk factor for retinal disease.
  • Jeito first invested in EyeBio in February 2022, just one year after its creation, as co-lead investor of a $65 million series A funding.
  • It has been tremendous to collaborate again, leveraging Jeito's collective expertise and steady financial support to accelerate breakthrough therapies.

FDA Grants Priority Review to Merck’s Application for KEYTRUDA® (pembrolizumab) Plus Chemotherapy as First-Line Treatment of Patients With Unresectable Advanced or Metastatic Malignant Pleural Mesothelioma

Retrieved on: 
onsdag, maj 29, 2024
Oncology, FDA, Health, Clinical Trials, Pharmaceutical, Biotechnology, MSD, Patient, Progression-free survival, Risk, Food, PFS, PDUFA, Death, ASCO, Society, MRK, Annual general meeting, Pharmaceutical industry

The FDA has set a Prescription Drug User Fee Act (PDUFA), or target action, date of September 25, 2024.

Key Points: 
  • The FDA has set a Prescription Drug User Fee Act (PDUFA), or target action, date of September 25, 2024.
  • At 12 months, the estimated PFS rate was 26% for KEYTRUDA plus chemotherapy versus 17% for chemotherapy alone.
  • The ORR was significantly higher for KEYTRUDA plus chemotherapy versus chemotherapy alone (62% versus 38%, p
  • The safety profile of KEYTRUDA plus chemotherapy in this study was consistent with previously reported studies.

Merck to Acquire EyeBio

Retrieved on: 
onsdag, maj 29, 2024
Health, Diabetes, Clinical Trials, Pharmaceutical, Optical, Biotechnology, MSD, Slate, Wnt signaling pathway, Patient, Retina, Merck & Co., Ophthalmology, Citigroup, DME, Acquisition, WNT, Diabetic retinopathy, MRK, Centerview Partners, Multimedia, Paratriathlon, Gibson Dunn, Pharmaceutical industry

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Eyebiotech Limited (EyeBio), a privately held ophthalmology-focused biotechnology company, today announced that the companies have entered into a definitive agreement under which Merck, through a subsidiary, will acquire EyeBio.

Key Points: 
  • Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Eyebiotech Limited (EyeBio), a privately held ophthalmology-focused biotechnology company, today announced that the companies have entered into a definitive agreement under which Merck, through a subsidiary, will acquire EyeBio.
  • “The EyeBio team, under the leadership of Dr. David Guyer and Dr. Tony Adamis, has a strong track record of developing groundbreaking ophthalmology therapies.
  • “The EyeBio team has successfully assembled a pipeline of novel candidates with the potential to provide new treatment options for patients with retinal disease,” said Dr. David R. Guyer, chief executive officer and president, EyeBio.
  • Centerview Partners LLC acted as financial advisor to EyeBio and Skadden, Arps, Slate, Meagher & Flom LLP as the company’s legal advisors.

Merck Announces Phase 3 KEYNOTE-522 Trial Met its Overall Survival (OS) Endpoint in Patients With High-Risk Early-Stage Triple Negative Breast Cancer (TNBC)

Retrieved on: 
tisdag, maj 28, 2024
Research, Diabetes, Clinical Trials, Biotechnology, General Health, Pharmaceutical, Health, Science, Oncology, Other Science, MSD, Patient, Survival, Merck & Co., Lung cancer, FDA, Cervical cancer, Breast cancer, PCR, Cancer, CPS, OS, MRK, Data monitoring committee, PD-L1, TNBC, Pharmaceutical industry

At a pre-specified interim analysis conducted by an independent Data Monitoring Committee, KEYTRUDA demonstrated a statistically significant and clinically meaningful improvement in OS compared to pre-operative chemotherapy.

Key Points: 
  • At a pre-specified interim analysis conducted by an independent Data Monitoring Committee, KEYTRUDA demonstrated a statistically significant and clinically meaningful improvement in OS compared to pre-operative chemotherapy.
  • The safety profile of KEYTRUDA was consistent with that observed in previously reported studies; no new safety signals were observed.
  • Results will be presented at an upcoming medical meeting and shared with regulatory authorities.
  • Merck has a comprehensive clinical development program in various subtypes of breast cancer.

Merck Announces Third-Quarter 2024 Dividend

Retrieved on: 
tisdag, maj 28, 2024
Research, Diabetes, Clinical Trials, Biotechnology, General Health, Pharmaceutical, Health, Science, Oncology, Other Science, MSD, MRK

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the Board of Directors has declared a quarterly dividend of $0.77 per share of the company’s common stock for the third quarter of 2024.

Key Points: 
  • Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the Board of Directors has declared a quarterly dividend of $0.77 per share of the company’s common stock for the third quarter of 2024.
  • Payment will be made on July 8, 2024, to shareholders of record at the close of business on June 17, 2024.

Merck to Present New Data at 2024 ASCO Annual Meeting Demonstrating Advancements in Novel Oncology Treatment Approaches Across Broad Portfolio and Diverse Pipeline

Retrieved on: 
onsdag, maj 15, 2024
Research, FDA, Clinical Trials, Biotechnology, General Health, Pharmaceutical, Health, Science, Oncology, Other Science, MSD, HER2, BTC, Cisplatin, PBC, Brentuximab vedotin, HCC, INT, Merck & Co., Pros, Endometrial cancer, ADC, Abstract, Melanoma, Hepatocellular carcinoma, Physician, PD-L1, Quality of life (healthcare), TNBC, Pembrolizumab, Safety, NSCLC, Cancer, Carcinoma, ASCO, Society, Patient, AHCC, Lung cancer, Therapy, Radiation, Daiichi Sankyo, MRK, Conjugation, Webcast, Quality of life, Annual general meeting, Georgetown University, Pharmaceutical industry

New data being shared at the meeting showcase the company’s continued progress to advance clinical research for Merck’s broad portfolio and diverse pipeline of investigational candidates.

Key Points: 
  • New data being shared at the meeting showcase the company’s continued progress to advance clinical research for Merck’s broad portfolio and diverse pipeline of investigational candidates.
  • “This year’s ASCO is also particularly meaningful as we approach 10 years since KEYTRUDA was first approved in the U.S.
  • As Merck continues to build its broad oncology portfolio, the company will also present data at ASCO from its diverse pipeline of investigational candidates, many being evaluated in combination with KEYTRUDA.
  • Merck will hold an Oncology Investor Event to coincide with the 2024 ASCO Annual Meeting on Monday, June 3, 2024, 6 p.m. CT, at which senior management will provide an update on the company’s oncology strategy and program.

Merck Provides Update on Phase 3 KeyVibe-010 Trial Evaluating an Investigational Coformulation of Vibostolimab and Pembrolizumab as Adjuvant Treatment for Patients With Resected High-Risk Melanoma

Retrieved on: 
måndag, maj 13, 2024
Oncology, FDA, Health, Clinical Trials, Pharmaceutical, Biotechnology, MSD, Lung, Patient, INT, TIGIT, Pembrolizumab, Merck & Co., CD112, CD155, Disease, Safety, Data analysis, Cancer, Interim, Melanoma, Ligand, Lung cancer, IIB, RFS, MRK, Data monitoring committee, IIC, DMC, Pharmaceutical industry

The trial is evaluating the investigational coformulation of vibostolimab, an anti-TIGIT antibody, and pembrolizumab (KEYTRUDA®), Merck’s anti-PD-1 therapy, compared to KEYTRUDA alone, as adjuvant treatment for patients with resected high-risk melanoma (Stage IIB-IV).

Key Points: 
  • The trial is evaluating the investigational coformulation of vibostolimab, an anti-TIGIT antibody, and pembrolizumab (KEYTRUDA®), Merck’s anti-PD-1 therapy, compared to KEYTRUDA alone, as adjuvant treatment for patients with resected high-risk melanoma (Stage IIB-IV).
  • At a pre-planned analysis, data showed that the primary endpoint of recurrence-free survival (RFS) met the pre-specified futility criteria.
  • Merck has an extensive clinical development program evaluating the safety and efficacy of the vibostolimab and pembrolizumab coformulation alone and in combination with other agents in over 3,000 patients.
  • Ongoing Phase 3 studies evaluating the vibostolimab and pembrolizumab coformulation in lung cancer, which are routinely monitored by external data monitoring committees, include KeyVibe-003 , KeyVibe-006 , KeyVibe-007 and KeyVibe-008 .

Mitigating Muscle Loss Becoming More Vital, Global Cancer Cachexia Market Projected to Reach $3.3 Billion in 2024

Retrieved on: 
onsdag, maj 8, 2024
MSD, PFS, FDA, Pfizer, MRNA, News, Atrophy, Weight loss, Doctor of Philosophy, Vaccine, University of Toronto, PFE, Medicinal chemistry, Medicine, Genome, Moderna, Diagnosis, AstraZeneca, Prevalence, GEJ, University, CPS, HER2, Food, OTC, IHC, Cachexia, Pneumococcal conjugate vaccine, Messenger, Quality of life, RSV, Patient, Facial muscles, Professor, Oncology, Trastuzumab, Research, Incidence, Fatigue, EPS, Neoplasm, MUSL, MRK, Tafamidis, Progression-free survival, PALM, PD-L1, COVID-19, Growth, Pharmaceutical industry

Cachexia is a medical condition known as ‘wasting syndrome’ that causes severe weight loss, muscle loss, and loss of body fats.

Key Points: 
  • Cachexia is a medical condition known as ‘wasting syndrome’ that causes severe weight loss, muscle loss, and loss of body fats.
  • The Cancer Cachexia market refers to the segment of the healthcare industry focused on addressing the multifaceted challenges associated with cachexia in cancer patients.
  • A report from Custom Market Insights projects that the global Cancer Cachexia Market is expected to record a CAGR of 5.1% from 2024 to 2033.
  • In 2024, the market size is projected to reach a valuation of USD 3.3 Billion.

Merck Provides Update on Phase 3 KEYNOTE-B21 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus Chemotherapy, With or Without Radiotherapy, for Patients With Newly Diagnosed, High-Risk Endometrial Cancer After Surgery With Curative Intent

Retrieved on: 
torsdag, maj 9, 2024
Research, FDA, Clinical Trials, Biotechnology, General Health, Pharmaceutical, Health, Science, Oncology, Other Science, MSD, B21, Radiation, DFS, Paclitaxel, Food, Merck & Co., Immunotherapy, Eisai, Data monitoring committee, Rated R, PDUFA, ADC, Patient, Endometrial cancer, Cancer, MSI-H, Carboplatin, MRK, Pharmaceutical industry

The study’s other primary endpoint of overall survival (OS) was not formally tested since superiority was not reached for DFS.

Key Points: 
  • The study’s other primary endpoint of overall survival (OS) was not formally tested since superiority was not reached for DFS.
  • The safety profile of KEYTRUDA was consistent with that observed in previously reported studies; no new safety signals were identified.
  • Merck will work with investigators to share the results with the scientific community.
  • “We would like to thank all the patients, the investigators and our study collaborators for their participation in this trial.”
    In the U.S., KEYTRUDA has two approved indications in endometrial cancer.

Merck to Participate in the Bank of America Securities 2024 Healthcare Conference

Retrieved on: 
onsdag, maj 8, 2024
Managed Care, Biotechnology, Pharmaceutical, Health, MSD, PDT, EDT, Bank, Conference, MRK

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that Caroline Litchfield, executive vice president and chief financial officer, is scheduled to participate in a fireside chat at the Bank of America Securities 2024 Healthcare Conference on Wednesday, May 15, 2024, at 1:40 p.m. PDT / 4:40 p.m. EDT.

Key Points: 
  • Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that Caroline Litchfield, executive vice president and chief financial officer, is scheduled to participate in a fireside chat at the Bank of America Securities 2024 Healthcare Conference on Wednesday, May 15, 2024, at 1:40 p.m. PDT / 4:40 p.m. EDT.